Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL614886 Target Snapshot

RXF 393 · CELL-LINE · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
38,510Compounds
797Assays
31Approved Drugs
192.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Confirm a stable target identifier before relying on this context across project surfaces.

Review focus
Open DB context pending

Confirm a stable target identifier before relying on this context across project surfaces.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats RXF 393 as ChEMBL target CHEMBL614886. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
RXF 393
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614886
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether RXF 393 still has a stable protein naming contract across sources.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameRXF 393
Target TypeCELL-LINE
OrganismHomo sapiens
ChEMBL ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRXF 393
UniProt AccessionN/A

RXF 393

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as RXF 393.

Review nameRXF 393
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

31
Approved
13
Phase III
13
Phase II
5
Phase I
Assay Mix

Activity Type Distribution

IC50192.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL325041 9.04 IC50 0.9138 Clinical
CHEMBL159 8.84 IC50 1.439 Approved
CHEMBL334648 8.7 IC50 2.0 Preclinical
CHEMBL3545252 8.65 IC50 2.215 Approved
CHEMBL94657 8.47 IC50 3.41 Clinical
CHEMBL65 8.33 IC50 4.662 Preclinical
CHEMBL553025 8.29 IC50 5.065 Approved
CHEMBL18155 8.07 IC50 8.6 Preclinical
CHEMBL252164 8.07 IC50 8.598 Clinical
CHEMBL341800 8.0 IC50 10.0 Preclinical
Distribution

pChEMBL Value Distribution

18
5.0
28
5.5
16
6.0
11
6.5
7
7.0
6
7.5
6
8.0
3
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

MIDOSTAURIN
CHEMBL608533
Approved 2017
Properties Compare Identifier
PALBOCICLIB
CHEMBL189963
Approved 2015
Properties Compare Identifier
TEMSIROLIMUS
CHEMBL1201182
Approved 2007
Properties Compare Identifier
DASATINIB
CHEMBL5416410
Approved 2006
Properties Compare Identifier
SIROLIMUS
CHEMBL413
Approved 1999
Properties Compare Identifier
DOCETAXEL
CHEMBL3545252
Approved 1995
Properties Compare Identifier
VINORELBINE
CHEMBL553025
Approved 1994
Properties Compare Identifier
PACLITAXEL
CHEMBL428647
Approved 1992
Properties Compare Identifier
DOXORUBICIN
CHEMBL53463
Approved 1974
Properties Compare Identifier
CYTARABINE
CHEMBL803
Approved 1969
Properties Compare Identifier
VINBLASTINE
CHEMBL159
Approved 1965
Properties Compare Identifier
Assay Landscape

Assay Landscape

797
Total Assays
173
Tested Compounds
2
Assay Types
Functional — 790 assays, 173 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 790 173 5.7
ADME — 7 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 7 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine